Efficacy of vorinostat in a murine model of polycythemia vera

Blood

Volumn 119, Issue 16, 2012, Pages 3779-3789

  Akada, Hajime ^a   Akada, Saeko ^a   Gajra, Ajeet ^a   Bair, Alicia ^a   Graziano, Stephen ^a   Hutchison, Robert E ^a   Mohi, Golam ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOG1 PROTEIN; JANUS KINASE 2; KRUPPEL LIKE FACTOR 1 POTEIN; PLACEBO; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ERYTHROBLAST; GENE MUTATION; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENOMEGALY; THERAPY EFFECT;

EID: 84860316991     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-336743     Document Type: Article

References (50)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
2. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190-2198.
3. James C, Ugo V, Le Couedic JP, et al. Aunique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005; 434(7037):1144-1148. (Pubitemid 40663494)
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-1061. (Pubitemid 40386783)
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17): 1779-1790. (Pubitemid 40570926)
7. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
8. Zou H, Yan D, Mohi G. Differential biological activity of disease-associated JAK2 mutants. FEBS Lett. 2011;585(7):1007-1013.
9. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115(6):1131-1136.
10. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. J Clin Oncol. 2011;29(7): 789-796.
11. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385-395. (Pubitemid 28232083)
12. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397-409. (Pubitemid 28232084)
13. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-1457.
14. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25(1):7-22.
15. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23(17):3971-3993. (Pubitemid 46218700)
16. Milhem M, Mahmud N, Lavelle D, et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood. 2004; 103(11):4102-4110. (Pubitemid 38685350)
17. De Felice L, Tatarelli C, Mascolo MG, et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005;65(4): 1505-1513. (Pubitemid 40270180)
18. Bug G, Gul H, Schwarz K, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res. 2005;65(7): 2537-2541. (Pubitemid 40490047)
19. Araki H, Mahmud N, Milhem M, et al. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol. 2006;34(2006):140-149. (Pubitemid 43184319)
20. Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood. 2007;109(8): 3570-3578. (Pubitemid 46572552)
21. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26(9): 1351-1356. (Pubitemid 46328465)
22. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21(9):1892-1900. (Pubitemid 47299961)
23. Shi J, Zhao Y, Ishii T, et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res. 2007; 67(13):6417-6424. (Pubitemid 47037526)
24. Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009; 114(24):5024-5033.
25. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA. 2001;98(19):10833-10838. (Pubitemid 32878706)
26. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2004;101(52):18030-18035. (Pubitemid 40054069)
27. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247-1252. (Pubitemid 350106355)
28. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17): 3923-3931. (Pubitemid 46218695)
29. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166-173. (Pubitemid 46630509)
30. Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma. 2008;49(12): 2321-2327.
31. Wang X, Zhang W, Tripodi J, et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 2010;116(26): 5972-5982.
32. Lee J. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Ann Hematol. 2009;88(7):699-700.
33. Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008;22(4):740-747. (Pubitemid 351552623)
34. Grebien F, Kerenyi MA, Kovacic B, et al. Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood. 2008;111(9):4511-4522.
35. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008;111(12): 5663-5671.
36. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103(16):6224-6229.
37. Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera. N Engl J Med. 1974; 290(24):1382.
38. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002;100(8):3041-3044.
39. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005;105(4): 1768-1776. (Pubitemid 40223701)
40. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7(6):454-465. (Pubitemid 46834848)
41. Kim SI, Bresnick E. Transcriptional control of erythropoiesis: emerging mechanisms and principles. Oncogene. 2007;26(47):6777-6794. (Pubitemid 47585102)
42. Kerenyi MA, Orkin SH. Networking erythropoiesis. J Exp Med. 2010;207(12):2537-2541.
43. Friedman AD. Transcriptional control of granulocyte and monocyte development. Oncogene. 2007;26(47):6816-6828. (Pubitemid 47585105)
44. Kerr JS, Galloway S, Lagrutta A, et al. Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol. 2010;29(1):3-19.
45. Marubayashi S, Koppikar P, Taldone T, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest. 2010;120(10):3578-3593.
46. Wernig G, Gonneville JR, Crowley BJ, et al. The Jak2V617F oncogene associated with myelopro-liferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008; 111(7):3751-3759.
47. Xiong H, Du W, Zhang YJ, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog. 2012;51(2):174-184.
48. Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: over-expression of transcription factor NF-E2. Br J Haematol. 2005;129(1):138-150. (Pubitemid 40524062)
49. Irino T, Uemura M, Yamane H, et al. JAK2 V617F-dependent upregulation of PU. 1 expression in the peripheral blood of myeloproliferative neoplasm patients. PLoS One. 2011;6(7):e22148.
50. Kaufmann KB, Grunder A, Hadlich T, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med. 2012;209(1): 35-50.